Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Volunteer Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

NCT02873650
View directory record Official record
Conditions
Hepatic Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • DeBary, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 21, 2026, 1:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

NCT00001405
View directory record Official record
Conditions
Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked, Genetic Disease, Inborn
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 1:47 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327
View directory record Official record
Conditions
Schizophrenia, Memory Disorders, Cognition Disorders
Interventions
Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing, Placebo
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

NCT00839124
View directory record Official record
Conditions
Asthma, Hypersensitivity
Interventions
Clinical Center Reference Endotoxin (CCRE)
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 21, 2026, 1:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 1:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Long Wavelength Ultraviolet (UVA) and Visible Light on Melanocompetent Skin

NCT00478751
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

NCT03680131
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%
Drug
Lead sponsor
Edesa Biotech Inc.
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
14
States / cities
Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 21, 2026, 1:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging in Alzheimer's Disease

NCT00039702
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123] 5-I-A-85380
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 1:47 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

NCT05676489
View directory record Official record
Conditions
Healthy Volunteers, Recurrent Glioma, Brain Metastases From Extra-cranial Solid Tumors
Interventions
[F-18]MeFAMP PET
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Months to 89 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

NCT02620774
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Ceftolozane/tazobactam, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Study the Mechanisms of Acupuncture Through Functional Magnetic Resonance Imaging and Peripheral Neurosensory Testing

NCT00521547
View directory record Official record
Conditions
Healthy
Interventions
Electroacupuncture
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2007 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

NCT04144374
View directory record Official record
Conditions
Diabetes, Wound Infection, Healthy Volunteers
Interventions
Omadacycline, Microdialysis Catheter Insertion
Drug · Procedure
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Single Dose PK Study

NCT00610727
View directory record Official record
Conditions
Migraine
Interventions
Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg, Inhaled prochlorperazine 2.5 mg, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Inhaled placebo, Prochlorperazine 10 mg IV over 5 sec
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

NCT02530710
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

NCT03787225
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 21, 2026, 1:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Stimulation of the Human Nervous System

NCT00001780
View directory record Official record
Conditions
Demyelinating Disease, Healthy, Lysosomal Storage Disease, Motor Neuron Disease, Movement Disorder
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

NCT01367483
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
IV methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 21, 2026, 1:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases

NCT00840567
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Skin biopsy, Blood draw & sample
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

NCT01844739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NVN1000 4% Gel, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 21, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain

NCT00350532
View directory record Official record
Conditions
Pain
Interventions
clonidine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 1:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

NCT04618263
View directory record Official record
Conditions
Major Depressive Disorder, Excessive Sleepiness
Interventions
GATE-101
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 21, 2026, 1:47 AM EDT